The risk of progression of atherosclerosis is proportional to the increase in elevated<unk><unk> , hyperglycemia and dyslipidemia. Therefore, the control of hypertension, hyperglycemia and other features of metabolic syndrome deserves special attention in the prevention of mortality and morbidity due to coronary artery disease. In patients with established CAD, concomitant diabetes and/or renal dysfunction, the<unk><unk>  goal is 130/80-85 and the decision to lower<unk><unk>  depends on the total cardiovascular risk and the extent of target organ damage. Close monitoring and lifestyle changes may be indicated in low-risk patients without documented target organ damage. However, in high-risk patients with a sustained SBP of ≥140 mm Hg and/or DBP ≥90 mm Hg, the goal is to lower<unk><unk>  less than 140/90 with the help of combined drug therapy and life style modification. Anti-hypertensive therapies that have shown to significantly reduce cardiovascular mortality and morbidity in patients with coronary artery disease include diuretics, beta-blockers, ACEIs, ARBs and calcium channel blockers.
Chronic stable angina treatment blood pressure control
Chronic stable angina treatment aspirin
Chronic stable angina treatment diabetes control
Chronic stable angina treatment physical activity
Chronic stable angina treatment calcium channel blockers
Chronic stable angina treatment lipid management
Chronic stable angina treatment beta blockers
Chronic stable angina treatment anti-lipid agents